Party Drug Ecstasy Showing Great Promise Treating Severe PTSD, Now In Final Clinical Trials

The pioneering clinical trials are sponsored by the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS), which since 1986 has created awareness around psychedelics as a healing modality. The organization has raised over $70 million developing such groundbreaking therapies – with more than half of that amount going specifically to MDMA-assisted PTSD work, currently in Phase 3 trials.